Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldeberlimab plus carboplatin, etoposide, and fluzoparib followed by aldeberlimab plus fluzoparib maintenance in first-line extensive-stage small cell lung cancer
ChiCTR2400083241Phase 2Recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Apr 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of adebezilimab, fluzoparib, carboplatin and etoposide, sponsored by Shanxi Bethune Hospital. Started Apr 2024; status: recruiting.
02
Drugs
adebezilimabfluzoparibcarboplatinetoposide
Beyond the preview
Go deeper on ChiCTR2400083241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083241.